Dormancy-Focused Agents and Adjuncts

Examples of drugs, repurposed agents, and compounds discussed in relation to dormant or slow-cycling cancer cells

This page is for team discussion.

It is not treatment advice.

Most agents below have mixed evidence, limited human data, or very context-specific use.

Dormancy-focused treatment does not mean one standard protocol exists.

It means some agents fit one of two broad ideas:

Agent or approach	Main dormancy-relevant action	Main caution or limit
Hydroxychloroquine or Withaferin A	Autophagy inhibition aimed at a common dormant-cell survival pathway see Autophagy page	Human oncology use is still combination-based and context dependent
Fisetin, quercetin, apigenin	To flip cell death switch ON in dormant cells. See Senolytic Pulse page	Supplement quality, dosing, and interactions still matter

whether the agent fits the biology of the case
whether the goal is maintenance, reactivation, or direct kill
whether there is meaningful human evidence
whether drug interactions, liver burden, or cardiometabolic risks change the balance

Dormancy-focused agents are best understood as discussion starters, not ready-made one-size-fits-all protocols.

The strongest use of this page is to help clarify that there is different approaches to the dormancy factor really worth thinking about carefully.

Novel Strategies to Combat Dormant Disseminated Tumor Cells
https://pmc.ncbi.nlm.nih.gov/articles/PMC8111294/

Navigate this section